Comparison of the Efficacy of Nal-IRI+5FU/LV and S-1 in Patients with Advanced Pancreatic Cancer Refractory to Gemcitabine and Nab-Paclitaxel
Nal-IRI+5-FU/LV and S-1 were equally effective and safe as second-line therapy for PC. However, the results suggest that S1 is an option for younger patients, especially those under 65 years.
Authors
- Kensuke Takuma (ORCID: https://orcid.org/0000-0003-3294-8990)
- Takahisa Matsuda
- Naoki Okano (ORCID: https://orcid.org/0000-0002-9759-1374)
- Yoshinori Kikuchi (ORCID: https://orcid.org/0000-0001-6070-6927)
- Susumu Iwasaki (ORCID: https://orcid.org/0000-0001-8390-6032)
- Yusuke Kimura
- Kazuhisa Yamaguchi (ORCID: https://orcid.org/0000-0003-0494-9427)
Institutions
- Toho University (JP)
- Toho University Omori Medical Center (JP)
Publication Details
- Journal
- Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1159/000543027
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00